BIOMARIN PHARMACEUTICAL INC Lease, Cost
BIOMARIN PHARMACEUTICAL INC (BMRN) reported Lease, Cost of $13.06 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-02-26
- BIOMARIN PHARMACEUTICAL INC lease, cost for the quarter ending 2020-12-31 was $4.95M, a 22.63% increase year-over-year.
- BIOMARIN PHARMACEUTICAL INC lease, cost for the quarter ending 2020-09-30 was $4.18M, a 2.29% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC lease, cost for the quarter ending 2020-06-30 was $3.85M, a 3.43% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC lease, cost for the quarter ending 2020-03-31 was $3.58M, a 6.96% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC lease, cost for fiscal 2025 was $13.06M, a 17.63% decline from fiscal 2024.
- BIOMARIN PHARMACEUTICAL INC lease, cost for fiscal 2024 was $15.86M, a 21.49% decline from fiscal 2023.
- BIOMARIN PHARMACEUTICAL INC lease, cost for fiscal 2023 was $20.20M, a 21.06% increase from fiscal 2022.
- BIOMARIN PHARMACEUTICAL INC lease, cost for fiscal 2022 was $16.69M, a 5.08% decline from fiscal 2021.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month |
|---|---|---|---|---|
| 2025-12-31 | $13.06M 10-K · filed 2026-02-26 | |||
| 2024-12-31 | $15.86M 10-K · filed 2026-02-26 | |||
| 2023-12-31 | $20.20M 10-K · filed 2026-02-26 | |||
| 2022-12-31 | $16.69M 10-K · filed 2024-02-26 | |||
| 2021-12-31 | $17.58M 10-K · filed 2023-02-27 | |||
| 2020-12-31 | $4.95M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $9.13M derived: sum of 2 quarters · filed 2022-02-25 | $12.98M derived: sum of 3 quarters · filed 2022-02-25 | $16.56M 10-K · filed 2022-02-25 |
| 2020-09-30 | $4.18M 10-Q · filed 2020-11-06 | $8.03M derived: sum of 2 quarters · filed 2020-11-06 | $11.61M 10-Q · filed 2020-11-06 | $15.65M derived: sum of 4 quarters · filed 2021-02-26 |
| 2020-06-30 | $3.85M 10-Q · filed 2020-08-05 | $7.43M 10-Q · filed 2020-08-05 | $11.47M derived: sum of 3 quarters · filed 2021-02-26 | $15.74M derived: sum of 4 quarters · filed 2021-02-26 |
| 2020-03-31 | $3.58M 10-Q · filed 2020-05-01 | $7.62M derived: sum of 2 quarters · filed 2021-02-26 | $11.89M derived: sum of 3 quarters · filed 2021-02-26 | $15.88M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-12-31 | $4.04M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $8.31M derived: sum of 2 quarters · filed 2021-02-26 | $12.30M derived: sum of 3 quarters · filed 2021-02-26 | $16.25M 10-K · filed 2021-02-26 |
| 2019-09-30 | $4.28M 10-Q · filed 2020-11-06 | $8.27M derived: sum of 2 quarters · filed 2020-11-06 | $12.21M 10-Q · filed 2020-11-06 | |
| 2019-06-30 | $3.99M 10-Q · filed 2020-08-05 | $7.94M 10-Q · filed 2020-08-05 | ||
| 2019-03-31 | $3.85M 10-Q · filed 2020-05-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |